Palvella COO Logs Third Month of Open-Market Sales
NEW YORK, July 23 —
Kathleen Goin, Palvella Therapeutics' chief operating officer, sold 4,302 shares on July 15 for approximately $642,000, the third consecutive month she has made open-market sales in an identical lot size. The transaction came one day after Palvella filed a material-event disclosure with the SEC, and within a week of a roughly 10% single-session decline in PVLA shares.
- $1.59 million in net insider sales over 90 days, zero purchases, all from Goin's three rounds of open-market transactions (per SEC Form 4 filings)
- PVLA shares fell approximately 10% on or around July 21, per Quiver Quantitative
- Trailing twelve-month free cash flow: negative $22 million on zero revenue
The Same Lot, Three Months Running
Goin's Form 4 filings trace an unusually consistent cadence. On May 20, she sold 4,302 shares across three tranches at $110.35 to $111.89 per share, totaling approximately $476,000. On June 17, another 4,302 shares across three tranches at $110.26 to $112.23, totaling approximately $476,000. On July 15, 4,302 shares again — this time across four tranches at $147.14 to $150.25 — totaling approximately $642,000.
Three months, the same share count each time, multiple tranches executed on the same calendar date each month. That cadence is characteristic of a pre-scheduled trading program, though whether a formal Rule 10b5-1 plan governs these sales is not stated in the Form 4 filings. Those filings record $1.59 million in net sales and no purchases over the 90-day window.
Exercise at Seven Dollars, Sell at One-Fifty
The July round differed structurally from May and June. Before selling, Goin first exercised two tranches of options: 2,154 shares at a $7.14 strike and 2,148 shares at $9.08, per Form 4 filings. She then sold the resulting 4,302 shares at $147.14 to $150.25 each. The spread between the $7.14 strike and a $150 sale price runs to roughly $143 per share on that lot.
Exercise-and-sell transactions are standard in executive compensation, and a $7 strike on stock trading near $150 reflects a long-dated options grant that has accumulated considerable value. Palvella remains a pre-revenue company carrying negative $22 million in trailing free cash flow. A stock price implying substantial future growth, combined with a COO converting deep-in-the-money options at scale across three consecutive months, is the kind of pattern investors in early-stage biotechs routinely flag for further examination.
A Filing, Then a Move
One day before Goin's option exercise and sale, Palvella filed an 8-K under Item 8.01, the SEC's catch-all category for material events outside the named disclosure buckets. The filing sits in the public record; its proximity to the insider transaction is the kind of sequencing that market participants track.
June produced its own disclosures. Palvella filed two 8-Ks related to officer appointments or departures: one on June 16, which also covered a shareholder vote, and one on June 30. The June 16 filing landed the day before Goin's second round of sales, repeating the same one-day sequencing seen in July.
What to Watch
H.C. Wainwright reiterated its buy rating on Palvella Therapeutics as of July 23, a signal that analyst conviction and insider monetization can coexist when the thesis rests on clinical milestones rather than near-term earnings. Three things merit watching: whether Goin's program produces a fourth consecutive August sale at the same lot size, what the July 14 8-K actually disclosed, and how the company's cash burn develops ahead of any potential capital raise.
Run the free Palvella Therapeutics, Inc. deep-dive →
Basis Report does not hold positions in securities discussed. This is not investment advice.
Frequently Asked Questions
Is the Palvella Therapeutics COO selling stock?
Yes. Chief Operating Officer Kathleen Goin has sold 4,302 shares in each of three consecutive months — May, June, and July 2026 — in open-market transactions totaling approximately $1.59 million. No insider purchases have been recorded over the same 90-day period, per SEC Form 4 filings.
What did Palvella's July 2026 8-K disclose?
Palvella filed an 8-K on July 14, 2026 under Item 8.01, the SEC's general "Other Events" category for material disclosures that do not fit named buckets. The filing was made one day before the COO's option exercise and stock sale. The full contents are publicly available on the SEC's EDGAR system.
Is Palvella Therapeutics profitable?
No. Palvella is a pre-revenue company with trailing twelve-month free cash flow of negative $22 million. The stock's valuation reflects investor expectations around future clinical outcomes rather than current financial performance.
What is the analyst rating on Palvella Therapeutics?
H.C. Wainwright reiterated a buy rating on Palvella Therapeutics as of July 23, 2026. Analyst ratings on pre-revenue biotechs typically reflect pipeline assessments and probability-weighted clinical milestones rather than near-term earnings metrics.
Why did PVLA stock drop 10% in July 2026?
PVLA shares fell approximately 10% on or around July 21, 2026, per Quiver Quantitative. The specific catalyst was not identified in available information. The decline followed an 8-K filing on July 14 and Goin's open-market sale of approximately $642,000 in shares on July 15.